Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

2.1K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo gene therapy with CAR-T cells.

Blood·2026
Same author

TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

Blood·2026
Same author

Lung tumouroids as a testing platform for precision CAR T cell therapy.

Nature biomedical engineering·2026
Same author

Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors.

Nature communications·2025
Same author

HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.

Nature communications·2025
Same author

Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.

Journal for immunotherapy of cancer·2025

Related Experiment Video

Updated: Jan 17, 2026

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

14.4K

Next-generation multiplex-edited CAR-NK cells: more edits, more power?

Tobias Bexte1,2,3, Dimitrios L Wagner3,4,5,6

  • 1Department of Pediatrics, Experimental Immunology and Celltherapy, Goethe University Frankfurt, Frankfurt am Main, Germany bexte@med.uni-frankfurt.de.

Journal for Immunotherapy of Cancer
|September 15, 2025
PubMed
Summary

CRISPR base editing enhances chimeric antigen receptor (CAR)-natural killer (NK) cell therapy by optimizing NK cell function and potency. This novel approach shows promise for off-the-shelf cell therapies but requires further investigation into potential organ toxicity before clinical application.

Keywords:
Adoptive cell therapy - ACTChimeric antigen receptor - CARImmune Checkpoint InhibitorImmunotherapyNatural killer - NK

More Related Videos

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins
07:20

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Published on: June 14, 2018

13.1K
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
09:51

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

35.5K

Related Experiment Videos

Last Updated: Jan 17, 2026

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

14.4K
Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins
07:20

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Published on: June 14, 2018

13.1K
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
09:51

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

35.5K

Area of Science:

  • Immunology
  • Molecular Biology
  • Biotechnology

Background:

  • Allogeneic natural killer (NK) cells are promising for "off-the-shelf" chimeric antigen receptor (CAR)-immune cell therapy.
  • Reduced NK cell persistence and inactivation by immunosuppressive factors limit current CAR-NK cell therapy efficacy.

Purpose of the Study:

  • To optimize the intrinsic functionality of CAR-NK cells using multiplex CRISPR base editing.
  • To enhance the therapeutic potential and potency of CAR-NK cells for cancer immunotherapy.

Main Methods:

  • Multiplex CRISPR base editing was employed to modify multiple sites in NK cells simultaneously, avoiding double-stranded DNA breaks.
  • A non-viral, single electroporation method was used to integrate CAR transgenes and edit immune checkpoints in NK cells.
  • In vitro assays and xenograft mouse models were utilized to assess the potency and safety of edited CAR-NK cells.

Main Results:

  • CRISPR base editing efficiently modified up to six sites in NK cells, enhancing their functionality.
  • CAR-NK cells with up to three base edits exhibited improved in vitro potency compared to unedited cells.
  • In vivo studies in mouse models demonstrated increased CAR-NK cell potency but also revealed potential organ toxicity.

Conclusions:

  • CRISPR base editing is a powerful tool for enhancing the cytotoxic potential of CAR-NK cells.
  • The study highlights the therapeutic promise of base-edited CAR-NK cells for off-the-shelf applications.
  • Further research is necessary to address observed organ toxicity and ensure the safety of CAR-NK cell therapy before clinical translation.